^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CCR8 inhibitor

    Related drugs:
    25d
    IPG7236 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=196, Recruiting, Nanjing Immunophage Biotech Co., Ltd | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    IPG7236
    2ms
    Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=376, Recruiting, Gilead Sciences | N=216 --> 376 | Trial completion date: Feb 2027 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Yutuo (zimberelimab) • GS-1811
    2ms
    aCCeleR8-001: S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=274, Recruiting, Shionogi | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy • Checkpoint inhibition • Metastases
    |
    Keytruda (pembrolizumab) • S-531011
    2ms
    A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=515, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab)
    3ms
    Study of CHS-114 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=47, Recruiting, Coherus Biosciences, Inc. | Phase classification: P1/2 --> P1 | N=70 --> 47
    Phase classification • Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    CHS-114
    5ms
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=318, Recruiting, BeiGene
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab) • BGB-A3055
    6ms
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=318, Recruiting, BeiGene | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab) • BGB-A3055
    7ms
    Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=24, Terminated, LaNova Medicines Limited | N=54 --> 24 | Trial completion date: Dec 2023 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Aug 2023; Completed primary objective.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • LM-108
    7ms
    Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies (clinicaltrials.gov)
    P1, N=146, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | N=82 --> 146
    Enrollment change • Metastases
    8ms
    Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=54, Recruiting, LaNova Medicines Limited | Trial completion date: Sep 2024 --> Dec 2023 | Trial primary completion date: Jul 2024 --> Nov 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • LM-108
    8ms
    Anti-CCR8 antibody CHS-114 (SRF114) depletes tumor-infiltrating regulatory T cells in dissociated tumors from patients with head and neck squamous cell carcinoma (SITC 2023)
    Molecular epidemiology studies highlight HNSCC as a tumor type with a high prevalence of CCR8+ itTregs to evaluate the anti-tumor activity of an anti-CCR8 antibody. CHS-114 (SRF114) is currently being evaluated in a Phase 1 clinical trial (NCT05635643).
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • FOXP3 (Forkhead Box P3) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression • FOXP3 expression
    |
    CHS-114
    9ms
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=318, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • IO biomarker • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    PD-L1 expression • CCR8 expression
    |
    Tevimbra (tislelizumab) • BGB-A3055
    10ms
    First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors (ESMO 2023)
    In dose expansion, patients with R/R non-small cell lung cancer will be enrolled in ABBV-514 monotherapy (N=12) and ABBV-514 + BDG (N=12) cohorts, and patients with R/R head and neck squamous cell carcinoma in an ABBV-514 + BDG (N=12) cohort. Enrollment initiated in November 2021, with 30 patients enrolled as of April 2023.
    Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    budigalimab (ABBV-181) • ABBV-514
    11ms
    Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=216, Recruiting, Gilead Sciences | N=158 --> 216 | Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Feb 2024 --> Jun 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Yutuo (zimberelimab) • GS-1811
    1year
    A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Zai Lab (Hong Kong), Ltd.
    New P1 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • ZL-1218
    1year
    Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer. (PubMed, J Med Chem)
    IPG7236 alone or in combination with PD-1 antibody exhibited significant tumor suppression effects in the mouse xenograft model of human breast cancer. IPG7236 is a promising clinical candidate that targets CCR8 with excellent in vitro ADMET properties, pharmacokinetics, safety profiles, and in vivo efficacy.
    Journal
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    IPG7236
    over1year
    Study of SRF114 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Surface Oncology | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    CHS-114
    over1year
    Study of SRF114 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Not yet recruiting, Surface Oncology
    New P1/2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    CHS-114
    over1year
    HBM1022: an afucosylated anti-CCR8 antibody, depletes specifically tumor infiltrating Tregs and inhibits tumor growth with excellent safety profile in preclinical studies (SITC 2022)
    HBM1022 exhibits a potent antitumor activity as monotherapy and in combination with anti-PD (L)1 antibodies. HBM1022 has favorable pharmacokinetic properties and an excellent safety profile in cynomolgus monkey, which suggests a potential good safety profile in human.
    Preclinical • IO biomarker
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    HBM1022
    2years
    Effective depletion of tumor-infiltrating Tregs by a novel anti-CCR8 antibody (LM-108): Addressing resistance associated with immune checkpoint inhibitors (AACR 2022)
    To conclude, LM-108 is a novel Fc-optimized CCR8 antibody that selectively depletes tumor infiltrating Tregs thereby improving anti-tumor immune response either as monotherapy or combination therapy. Thus, LM-108 can be a promising therapeutic approach to overcome ICI resistance in cancer patients.
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CCR4 (C-C Motif Chemokine Receptor 4) • FOXP3 (Forkhead Box P3) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression • FOXP3 expression
    |
    LM-108
    2years
    ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells (AACR 2022)
    We are currently exploring the significance of these distinct populations and the impact of ZL-1218-mediated depletion of both CCR8 high- and CCR8 low-expressing subsets in multiple indications. Together, these data support the advancement of ZL-1218 into clinical evaluation as a novel therapeutic candidate to treat human solid tumors.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression
    |
    ZL-1218
    over2years
    Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones? (PubMed, Cancers (Basel))
    We also discuss the possibility of targeting the function or deleting a key subset of T that are CCR8 by monoclonal antibodies to CCR8. These cells are preferentially abundant in several tumors and are likely to be the key drivers in suppressing anti-cancer immune reactivity.
    Review • Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCR8 (C-C Motif Chemokine Receptor 8) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    over2years
    Single-cell profiling defines the prognostic benefit of CD39 tissue resident memory CD8+ T cells in luminal-like breast cancer. (PubMed, Commun Biol)
    Nevertheless, such prognostic benefit is lost in the presence of highly-suppressive CCR8 ICOS IRF4+ effector Tregs. Thus, combinatorial strategies aiming at boosting Trm function and infiltration while relieving from Treg-mediated immunosuppression should be investigated to achieve proper tumor control in luminal-like BCs.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL7R (Interleukin 7 Receptor) • ICOS (Inducible T Cell Costimulator) • CCR8 (C-C Motif Chemokine Receptor 8) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    over2years
    [VIRTUAL] Immune-Related Signature Genes Expression in Non-Tumor and Solid Tumor Tissue Associated with Tertiary Lymphoid Structures (AMP 2021)
    The upregulation of signature genes associated with effector T-cells, monocytes, and exhausted Tcells in tumor tissue demonstrated that tumor-derived factors modify the function of TLS in generating an anti-tumor immune response. These findings also help us to further focus our efforts on studying the role of monocytes in TIME.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD22 (CD22 Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD33 (CD33 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • CCL19 (C-C Motif Chemokine Ligand 19) • CD14 (CD14 Molecule) • FOXP3 (Forkhead Box P3) • GZMA (Granzyme A) • CCR8 (C-C Motif Chemokine Receptor 8) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • MS4A1 (Membrane Spanning 4-Domains A1)
    over2years
    Distinct expression profile of chemokine receptors is associated with the pathogenesis of follicular lymphoma (DGHO 2021)
    Overall, our results indicate that a distinct chemokine receptor pattern might implicate the development and early progression of FL. Thus, several receptors might serve as a useful clinical prognostic marker for risk stratification and / or as a potential novel therapeutic target for lymphoma therapy.
    IO biomarker
    |
    CCR4 (C-C Motif Chemokine Receptor 4) • CCR5 (C-C Motif Chemokine Receptor 5) • CCR7 (Chemokine (C-C motif) receptor 7) • CCR8 (C-C Motif Chemokine Receptor 8) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    |
    CCR5 expression
    over2years
    S-531011, a novel anti-human CCR8 antibody: anti-tumor responses through depletion of tumor-infiltrating CCR8-positive Tregs (SITC 2021)
    On the other hand, S-531011 didn’t reduce Tregs in human PBMC. Conclusions S-531011 is a promising drug which has a strong antitumor effect by depleting tumor-infiltrating CCR8+ Tregs, as a not only monotherapy but also combination therapy with other immune checkpoint inhibitors.
    PD(L)-1 Biomarker • IO biomarker
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression
    |
    S-531011
    almost3years
    A multi-cellular molecular signaling and functional network map of C-C motif chemokine ligand 18 (CCL18): a chemokine with immunosuppressive and pro-tumor functions. (PubMed, J Cell Commun Signal)
    Characterization of the molecular events and check points associated with the immunosuppressive and cancer progression support functions induced by CCL18 for their potential towards therapeutic applications is an area of active research. Hence, in this study, we assembled 917 signaling events reported to be induced by CCL18 through their studied receptors in diverse cell types as an integrated knowledgebase for reference, data integration and gene-set enrichment analysis of global transcriptomic and/or proteomics datasets.
    Journal
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    almost3years
    Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. (PubMed, Int Immunopharmacol)
    Our findings suggest that P2RY12 is an immune infiltration-related prognostic marker for LUAD.
    Journal
    |
    CCR8 (C-C Motif Chemokine Receptor 8) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    almost3years
    Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. (PubMed, Sci Adv)
    This sustained and improved infiltration of engineered T cells synergized with TGF-β shielding for improved therapeutic efficacy. Our results demonstrate that addition of CCR8 and DNR into CAR T cells can render them effective in solid tumors.
    Clinical • Journal • CAR T-Cell Therapy
    |
    TGFB1 (Transforming Growth Factor Beta 1) • CCR8 (C-C Motif Chemokine Receptor 8)
    almost3years
    Immunomodulation of T Helper Cells by Tumor Microenvironment in Oral Cancer Is Associated With CCR8 Expression and Rapid Membrane Vitamin D Signaling Pathway. (PubMed, Front Immunol)
    Finally, we evaluated the presence of CCR8 ligand in OSCC and observed increased chemokine CCL18, which was also able to upregulate CCR8 in activated Th cells. Overall, our data showed the immunomodulatory changes induced by the TME involving CCR8 expression and regulatory Th2 phenotypes, which are associated with PGE2 mediated VitD signaling pathway and CCL18 expression in OSCC.
    Journal
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression
    3years
    CCL1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous Cell Carcinoma Progression via CCR8-mediated Akt/PRAS40/mTOR Pathway. (PubMed, Am J Pathol)
    The overexpression of CCL1 in stromal cells or CCR8 in ESCC cells was significantly associated with poor overall survival (P = 0.002 or 0.009) and disease-free survival (P = 0.009 or 0.047) in ESCC patients. These results indicated that the interaction between stromal CCL1 and CCR8 on cancer cells promotes ESCC progression via the Akt/PRAS40/mTOR pathway, providing novel therapeutic targets.
    Journal
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    QTORIN 3.9% (rapamycin topical)
    3years
    CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function. (PubMed, Immunology)
    Consistently, we observed minimal impact of systemic CCR8 ablation on the frequency, phenotype and function of tumour-infiltrating Treg cells and conventional T (Tconv) function. These findings suggest that CCR8 is not required for Treg cell accumulation and immunosuppressive function within tumours and that depletion of CCR8 Treg cells rather than blockade of CCR8 function is a more promising avenue for selective immunotherapy.
    Journal • IO biomarker
    |
    CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression
    3years
    CCR4, CCR8, and P2RY14 as Prognostic Factors in Head and Neck Squamous Cell Carcinoma Are Involved in the Remodeling of the Tumor Microenvironment. (PubMed, Front Oncol)
    CIBERSORT results showed that the expression of these genes was all negatively correlated with the fraction of memory B cells and positively correlated with the fraction of the other four cells, including naive B cells, resting T cells CD4 memory, T cells follicular helper, and T cells regulatory (Tregs). The results suggest that CCR4, CCR8, and P2RY14 may be responsible for maintaining the immune dominance of TME, thus leading to a better prognosis.
    Journal • IO biomarker
    |
    CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule) • CCR8 (C-C Motif Chemokine Receptor 8)
    3years
    [VIRTUAL] Humanized CCR8 mouse model provides a translational tool for anti-human CCR8 antibody drug development (AACR 2021)
    The human CCR8 protein were successfully detected in tumor-infiltrating Tregs in B-hCCR8 mice bearing MC38 tumor, but not in Treg cells from spleen. An anti-tumor efficacy study showed significant tumor growth inhibition of hCCR8 antibodies in B-hCCR8 mice bearing MC38 tumors, suggesting that the B-hCCR8 mouse model is an effective tool for in vivo efficacy evaluation of therapeutic hCCR8 antibodies to support anti-human CCR8 antibody clinical development.
    Preclinical
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • IL10 (Interleukin 10) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3) • CCR8 (C-C Motif Chemokine Receptor 8) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    CCR8 expression • FOXP3 expression
    3years
    CDCA3 Is a Novel Prognostic Biomarker Associated with Immune Infiltration in Hepatocellular Carcinoma. (PubMed, Biomed Res Int)
    Moreover, CDCA3 expression was associated with gene markers such as PD-1, CTLA4, LAG3, and TIM-3 from exhausted T cells, CD3D, CD3E, and CD2 from T cells, and TGFB1 and CCR8 located on the surface of Tregs. Thus, we demonstrated that CDCA3 may be a potential target and biomarker for the management and diagnosis of HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1) • CCR8 (C-C Motif Chemokine Receptor 8) • CD2 (CD2 Molecule)
    3years
    Therapeutic depletion of CCR8 tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. (PubMed, J Immunother Cancer)
    Collectively, our findings highlight the efficacy and safety of targeting CCR8 for the depletion of tumor-promoting ti-Tregs in combination with anti-PD-1 therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression
    over3years
    CC Chemokine Receptors in Lung Adenocarcinoma: The Inflammation-Related Prognostic Biomarkers and Immunotherapeutic Targets. (PubMed, J Inflamm Res)
    Moreover, the Cox proportional hazard model showed that CCR1/2/10, B_cell, CD4_Tcell were significantly related to the clinical outcome of LUAD patients. CC chemokine receptors might serve as immunotherapeutic targets and prognostic biomarkers in LUAD.
    Journal • IO biomarker
    |
    CCR4 (C-C Motif Chemokine Receptor 4) • CCR7 (Chemokine (C-C motif) receptor 7) • CCR8 (C-C Motif Chemokine Receptor 8)
    over3years
    CD30OX40 Treg is associated with improved overall survival in colorectal cancer. (PubMed, Cancer Immunol Immunother)
    Consistently, multiplex-IHC/IF of tumor-infiltrating Tregs revealed a significant association between high densities of CD30OX40 Tregs and improved overall survival; no such association was found for other subsets. These data suggest a potential role for CD30OX40 Tregs as a diagnostic or prognostic biomarker in CRC.
    Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TNFRSF4 (TNF Receptor Superfamily Member 4) • CCR8 (C-C Motif Chemokine Receptor 8) • IL1R1 (Interleukin 1 receptor, type I)
    |
    TNFRSF8 expression • TNFRSF4 expression
    over3years
    TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma. (PubMed, Front Genet)
    In conclusion, TMEM205 might improve HCC patients' prognosis by reducing the levels of immunosuppressive cells (M2 macrophages and Tregs) and facilitating the infiltration of cytotoxic T cells into the tumor microenvironment. Therefore, TMEM205 has potential as a prognostic biomarker and immunotherapy agent in combination therapy regimens for HCC.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • STAT5B (Signal Transducer And Activator Of Transcription 5B)
    over3years
    Tumorigenesis-related key genes in adolescents and young adults with HR(+)/HER2(-) breast cancer. (PubMed, Int J Clin Exp Pathol)
    The key genes CXCL2, CXCL5, CXCL3, GPR37L1, NPY2R, OXGR1, NPW, CCL21, GNAI1, SAA1, GRM4, HCAR2, CX3CL1, GRM8, CCL28, SSTR1, PENK, P2RY12, NMUR1, NMU, ADCY5, TAS1R1, OXER1, GNG13, CCL16, CCR8, NPY5R, CXCL11, CXCL10, CXCL9, CXCL1, CXCL6, CCR4, and ANXA1 may be molecular markers of tumorigenesis of HR(+)/HER2(-) BC in AYAs. In addition, ether lipid metabolism and complement and coagulation cascades may be key pathways for GNAI1 regulation in HR(+)/HER2(-) BC in AYAs.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • SAA1 (Serum Amyloid A1) • ANXA1 (Annexin A1) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    HR positive • HER-2 negative